Previous close | 0.0512 |
Open | 0.0480 |
Bid | 0.0464 x 0 |
Ask | 0.0598 x 0 |
Day's range | 0.0512 - 0.0598 |
52-week range | 0.0303 - 0.0700 |
Volume | |
Avg. volume | 969 |
Market cap | 24.162M |
Beta (5Y monthly) | 0.97 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.0300 |
Earnings date | 27 Mar 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MediPharm Labs ( TSE:LABS ) Full Year 2023 Results Key Financial Results Revenue: CA$33.1m (up 50% from FY 2022). Net...
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, has released and hosted a conference call regarding its full year and fourth quarter financial results for the period ended December 31, 2023.
MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precision-based cannabinoids, today announced its financial results for the full year and three months ended December 31, 2023.